China Medical System - Public Comps and Valuation Multiples

China Medical System Overview

About China Medical System

China Medical System Holdings Ltd is active in the healthcare segment. It is one of the China-based pharmaceutical services companies in the country. The company's business mainly involves the marketing, promotion, and sales of prescription pharmaceutical products manufactured by domestic pharmaceutical companies. Some of its products include Plendil, Salofalk, Combizym, and others.

Founded

2006

HQ

Employees

4.7K+

Website

cms.net.cn

Sectors

Drug Development & Therapeutics
BioTech

Financials

LTM Revenue $1.2B

LTM EBITDA $308M

EV

$3.7B

Valuation Multiples

Multiples.vc

Valuation Multiples for 15K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

China Medical System Financials

As of September 2025, China Medical System reported last 12-month revenue of $1.2B and EBITDA of $308M.

In the same period, China Medical System generated $899M in LTM gross profit and $253M in net income.

See China Medical System valuation multiples based on analyst estimates

China Medical System P&L

In the most recent fiscal year, China Medical System reported revenue of $960M and EBITDA of $297M.

China Medical System expects next 12-month revenue of XXX and NTM EBITDA of XXX

See China Medical System valuation multiples based on analyst estimates

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue	$1.2B	XXX	$960M	XXX	XXX	XXX
Gross Profit	$899M	XXX	$697M	XXX	XXX	XXX
Gross Margin	73%	XXX	73%	XXX	XXX	XXX
EBITDA	$308M	XXX	$297M	XXX	XXX	XXX
EBITDA Margin	25%	XXX	31%	XXX	XXX	XXX
EBIT	$274M	XXX	$223M	XXX	XXX	XXX
EBIT Margin	22%	XXX	23%	XXX	XXX	XXX
Net Profit	$253M	XXX	$208M	XXX	XXX	XXX
Net Margin	20%	XXX	22%	XXX	XXX	XXX
Net Debt	XXX	XXX	n/a	XXX	XXX	XXX

Financial data powered by Morningstar, Inc.

.seo-only-financials-wrapper { position: static; left: auto; width: auto; height: auto; overflow: visible; }

Financial performance metrics for China Medical System including revenue, profitability, and margin analysis across different time periods. The company reported last twelve months revenue of $1.2B. EBITDA for the last twelve months was $308M. In the most recent fiscal year, China Medical System achieved $960M in revenue and $297M in EBITDA.
Financial Metric	Last Twelve Months (LTM)	Next Twelve Months (NTM)	Most Recent Fiscal Year	Current Fiscal Year (2025)	Next Fiscal Year (2026)	Two Years Forward (2027)
Total Revenue	$1.2B	Analyst estimates available to subscribers	$960M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit	$899M	Analyst estimates available to subscribers	$697M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit Margin	72.5% gross margin	Analyst estimates available to subscribers	72.6% gross profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA (Earnings Before Interest, Taxes, Depreciation, Amortization)	$308M	Analyst estimates available to subscribers	$297M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA Margin	24.8% EBITDA margin	Analyst estimates available to subscribers	30.9% EBITDA margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT (Earnings Before Interest and Taxes)	$274M	Analyst estimates available to subscribers	$223M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT Margin	22.1% EBIT margin	Analyst estimates available to subscribers	23.2% EBIT margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Income (Net Profit)	$253M	Analyst estimates available to subscribers	$208M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Profit Margin	20.4% net profit margin	Analyst estimates available to subscribers	21.7% net profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Debt Position	Detailed debt information available to subscribers	Detailed debt information available to subscribers	n/a	Detailed debt information available to subscribers	Detailed debt information available to subscribers	Detailed debt information available to subscribers

Financial Performance Summary for China Medical System

This financial data table provides comprehensive performance metrics for China Medical System, a company based in Hong Kong. The metrics include revenue, profitability measures, and operational efficiency indicators across multiple time periods.

Recent Performance Highlights

China Medical System generated $1.2B in revenue over the last twelve months.
The company achieved $308M in EBITDA over the last twelve months.
Gross profit for the last twelve months was $899M.
Net income over the last twelve months reached $253M.

Fiscal Year Performance

In the most recent fiscal year, China Medical System reported $960M in total revenue.
Fiscal year EBITDA was $297M.
The company maintained a gross profit margin of 72.6% in the most recent fiscal year.
EBITDA margin for the fiscal year was 30.9%.
Net profit margin reached 21.7% in the most recent fiscal year.

This financial data is sourced from Morningstar, Inc. and represents the most recent available information for China Medical System. Forward-looking estimates and detailed financial projections are available through our premium subscription service.

China Medical System Stock Performance

China Medical System has current market cap of HKD 34.3B (or $4.4B), and EV of HKD 28.6B (or $3.7B).

Market Cap Evolution

China Medical System Stock Data

As of October 3, 2025, China Medical System's stock price is HKD 14 (or $2).

See China Medical System trading valuation data

EV	Market Cap	Price 1D	Price 1M	Price 3M	Price 12M	EPS
$3.7B	$4.4B	XXX	XXX	XXX	XXX	$0.10

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Start Free Trial

China Medical System Valuation Multiples

China Medical System's trades at 3.8x EV/Revenue multiple, and 12.4x EV/EBITDA.

See valuation multiples for China Medical System and 15K+ public comps

China Medical System Financial Valuation Multiples

As of October 3, 2025, China Medical System has market cap of $4.4B and EV of $3.7B.

Equity research analysts estimate China Medical System's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

China Medical System has a P/E ratio of 19.0x.

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Market cap (current)	$4.4B	XXX	$4.4B	XXX	XXX	XXX
EV (current)	$3.7B	XXX	$3.7B	XXX	XXX	XXX
EV/Revenue	3.2x	XXX	3.8x	XXX	XXX	XXX
EV/EBITDA	13.0x	XXX	12.4x	XXX	XXX	XXX
EV/EBIT	14.6x	XXX	16.5x	XXX	XXX	XXX
EV/Gross Profit	4.5x	XXX	n/a	XXX	XXX	XXX
P/E	19.0x	XXX	21.2x	XXX	XXX	XXX
EV/FCF	18.3x	XXX	35.2x	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get China Medical System Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Start Free Trial

China Medical System Margins & Growth Rates

China Medical System's last 12 month revenue growth is 15%

China Medical System's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.1M for the same period.

China Medical System's rule of 40 is 55% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

China Medical System's rule of X is 63% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

See operational valuation multiples for China Medical System and other 15K+ public comps

China Medical System Operational Valuation Multiples

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue Growth	15%	XXX	19%	XXX	XXX	XXX
EBITDA Margin	25%	XXX	31%	XXX	XXX	XXX
EBITDA Growth	16%	XXX	-16%	XXX	XXX	XXX
Rule of 40	55%	XXX	46%	XXX	XXX	XXX
Bessemer Rule of X	XXX	XXX	63%	XXX	XXX	XXX
Revenue per Employee	XXX	XXX	$0.2M	XXX	XXX	XXX
Opex per Employee	XXX	XXX	$0.1M	XXX	XXX	XXX
S&M Expenses to Revenue	XXX	XXX	36%	XXX	XXX	XXX
G&A Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
R&D Expenses to Revenue	XXX	XXX	4%	XXX	XXX	XXX
Opex to Revenue	XXX	XXX	49%	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics

Pharma Analytics

Private Equity

ERP Software

Developer Tools

Consumer SaaS

Streaming Platforms

Explore Valuation Multiples by Industry

Start Free Trial